17-Methyleneestra-1,3,5(10)-trien-3-ol | 34111-53-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 17-Methyleneestra-1,3,5(10)-trien-3-ol
• 英文别名: 3-hydroxy-17-methyleneestra-1,3,5(10)-triene；17-Methylene-1,3,5-estratrien-3-ol；17-methylene estratriene；17-methylene-1,3,5(10)-estratrien-3-ol；13-methyl-17-methylene-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-ol；17-methylenestra-1,3,5(10)-trien-3-ol；(8S,9S,13S,14S)-13-methyl-17-methylidene-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-ol
• CAS: 34111-53-0
• 化学式: C₁₉H₂₄O
• 分子量: 268.399
• InChiKey: ZNDIUTIVPDDBNJ-AKHDSKFASA-N

物化性质

• 熔点：
  135-136 °C
• 沸点：
  410.3±45.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  17-Methyleneestra-1,3,5(10)-trien-3-ol 在 溴乙烷 、 magnesium 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.67h， 生成 3-(tert-butyldimethylsilyl)-2-formyl-17-methylene estratriene
  参考文献：
  名称：

  Synthesis of 2-substituted 17β-hydroxy/17-methylene estratrienes and their in vitro cytotoxicity in human cancer cell cultures

  摘要：

  Synthesis of various types of 2-(alkylaminomethyl) and 2-(aroyl) 17 beta-estradiol analogs are reported. The synthesis of similar types of 2-substituted 17-methylene estratriene analogs was also achieved. Synthesis of chalcone derivatives of 17 beta-estradiol and 17-methylene estratriene were also realized. All these 2-substituted estratrienes were tested for their antiproliferative activity by using four different cell lines from colon, lung, glioma and breast cancers. Among the various 2-substituted estratrienes, the compounds 10d, 14a-h and 17e were found to have in vitro antiproliferative activity comparable to that of parent analogs 1-4. Comparison of the SAR pattern of these 2-susbtituted estratriene derivatives confirmed that relatively, 17-methylene estratrienes are more active than that of 17 beta-estradiol analogs. (C) 2011 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.steroids.2011.08.004
• 作为产物：
  描述：

  2-[[(8S,9S,13S,14S)-13-methyl-17-methylidene-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl]oxy]oxane 生成 17-Methyleneestra-1,3,5(10)-trien-3-ol
  参考文献：
  名称：

  JUNGBLUT, PETER;WIECHERT, RUDOLF;BITTLER, DIETER

  摘要：

  DOI：

文献信息

• Steriod inhibitors of estrone sulfatase and associated pharmaceutical
  申请人：SRI International

  公开号：US05763432A1

  公开（公告）日：1998-06-09

  Novel compounds useful as inhibitors of estrone sulfatase are provided. The compounds have the structural formula (I) ##STR1## wherein X and Y, or Y and Z, form an oxathiazine dioxide ring or a dihydro-oxathiazine dioxide ring, and the other various substituents are as defined herein. Pharmaceutical compositions and methods for using the compounds of formula (I) to treat estrogen-dependent disorders are provided as well.

  提供了作为雌酮磺酸酶抑制剂有用的新化合物。这些化合物具有结构式（I）##STR1##其中X和Y，或Y和Z，形成一个氧硫氮二氧杂环或一个二氢氧硫氮二氧杂环，其他各种取代基如本文所定义。还提供了使用式（I）化合物治疗雌激素依赖性疾病的药物组合物和方法。
• [EN] OESTROGEN DERIVATIVES AS INHIBITORS OF STEROID SULPHATASE<br/>[FR] DERIVES ESTROGENES UTILISES EN TANT QU'INHIBITEURS DE STEROIDE SULFATASE
  申请人：STERIX LTD

  公开号：WO2004085459A1

  公开（公告）日：2004-10-07

  The present invention provides a compound comprising a steroidal ring system and an optional group R1 selected from any one of -OH, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; wherein the D ring of the steroidal ring system is substituted by a group R2 of the formula -L-R3, wherein L is an optional linker group and R3 is selected from groups which are or which comprise one of a nitrite group, an alcohol, an ester, an ether, an amine and an alkene, provided that when R3 is or comprises an alcohol, L is present; and wherein the A ring of the steroidal ring system is substituted at position 2 or 4 with a group R4, wherein R4 is a hydrocarbyl group.

  本发明提供一种化合物，包括一种甾体环系统和一个可选的基团R1，所述基团R1从以下任一基团中选择：-OH、磺酸酯基团、膦酸酯基团、硫代膦酸酯基团、磺酸基团或磺酰胺基团；其中所述甾体环系统的D环通过一个公式-L-R3的基团R2取代，其中L是一个可选的连接基团，R3选择自一个亚硝酸盐基团、醇基团、酯基团、醚基团、胺基团和烯烃基团中的一个或组成一个，条件是当R3是或包含一个醇基团时，L存在；以及所述甾体环系统的A环在位置2或4处被一个基团R4取代，其中R4是一个烃基团。
• Steroids as neurochemical initiators of change in human blood levels of
  申请人：Pherin Corporation

  公开号：US06066627A1

  公开（公告）日：2000-05-23

  The invention relates to a method of altering the blood levels of LH or FSH in an individual. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.

  该发明涉及一种改变个体血液中LH或FSH水平的方法。该方法包括经鼻给药一种类固醇物质，该类固醇物质是一种人类嗅觉素，使得该嗅觉素结合到特定的神经上皮受体上。该类固醇或多种类固醇最好以含有一个或多个药用载体的制药组合物的形式给药。
• Steroids as neurochemical stimulators of the VNO to alleviate symptoms
  申请人：Pherin Corporation

  公开号：US06057439A1

  公开（公告）日：2000-05-02

  The invention relates to a method of alleviating the symptoms of PMS and anxiety. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.

  该发明涉及一种缓解经前期综合征和焦虑症状的方法。该方法包括通过鼻腔给药一种类固醇物质，即一种人类呕吐素，使得呕吐素与特定的神经上皮受体结合。所述类固醇物质通常以含有一种或多种药用载体的药物组合物的形式给予。
• Steroids as neurochemical stimulators of the VNO to treat paroxistic
  申请人：Pherin Pharmaceuticals, Inc.

  公开号：US06117860A1

  公开（公告）日：2000-09-12

  The invention relates to a method of alleviating the symptoms of PMS and anxiety. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.

  该发明涉及一种缓解经前期综合症和焦虑症状的方法。该方法包括经鼻给药一种类固醇物质，即人类呕吐素，使得呕吐素与特定的神经上皮受体结合。该类固醇物质或多种类固醇物质最好以含有一种或多种药用载体的药物组合物的形式给予。